Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
Dengue
Human papillomavirus (HPV)
Meningococcal disease
SAGE documentation
Scientific publications
2018
2010
Clear all
Type of publications
NITAG documentation
(34)
Reports
(1)
SAGE documentation
(9)
Scientific publications
(8)
Systematic reviews (SYSVAC)
(16)
Topics
Evidence to recommendation table
(2)
GRADE table
(5)
Position paper
(2)
Available to download in languages
English (EN)
(16)
French (FR)
(6)
Portugese (PT)
(1)
Russian (RU)
(1)
Regions
Africa
(2)
Americas
(1)
Eastern Mediterranean
(1)
Europe
(1)
South-East Asia
(1)
Western Pacific
(2)
Countries
Diseases
Dengue
(8)
Human papillomavirus (HPV)
(8)
Meningococcal disease
(1)
Cholera
(1)
Ebola
(1)
Haemophilus influenzae type B
(4)
Hepatitis A
(1)
Influenza
(1)
Measles
(2)
Mumps
(1)
Poliomyelitis
(1)
Rabies
(2)
Rotavirus
(1)
Rubella
(1)
Tuberculosis
(7)
Typhoid
(1)
Vaccine topics
Target population
Publication date
2018
(10)
2010
(7)
2024
(4)
2022
(3)
2019
(1)
2017
(11)
2015
(9)
2014
(3)
2013
(1)
2011
(2)
2009
(2)
2008
(1)
17 results found
2018
∙
SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seronegative individuals 9-16 years of age in the first year following vaccination?
2018
∙
SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?
2018
∙
SAGE
Should countries considering introduction of CYD-TDV to reduce the burden of dengue use a pre-vaccination screening or population seroprevalence based criteria?
2018
∙
SAGE
Should CYD-TDV be recommended, over no vaccination, to immunocompetent individuals (≥9 years of age) in dengueendemic countries to mitigate the dengue burden of disease?
2018
∙
SAGE
What is the duration of protection/risk in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?
2018
∙
SAGE
What is the duration of protection/risk in seronegative individuals 9-16 years of age vaccinated with CYD-TDV?
2018
∙
SAGE
What is the risk of other serious adverse events (non-dengue) in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?
2018
∙
SAGE
Dengue vaccine: WHO position paper
2018
∙
Reza Yaesoubi, Caroline Trotter, Caroline Colijn, Maziar Yaesoubi, Anaïs Colombini, Stephen Resch, Paul A. Kristiansen
The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study
2018
∙
WHO
Summary of WHO Position Papers - Recommended Routine Immunizations for Children
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register